<DOC>
	<DOCNO>NCT01075555</DOCNO>
	<brief_summary>RATIONALE : Sorafenib tosylate pravastatin may stop growth tumor cell block enzymes need cell growth . Sorafenib tosylate may also stop growth liver cancer block blood flow tumor . It yet know whether sorafenib tosylate effective give alone together pravastatin treat patient liver cancer cirrhosis . PURPOSE : This randomized phase III trial study sorafenib tosylate give together pravastatin see well work compare give sorafenib tosylate alone treat patient liver cancer cirrhosis .</brief_summary>
	<brief_title>Sorafenib Tosylate With Without Pravastatin Treating Patients With Liver Cancer Cirrhosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate effect sorafenib tosylate pravastatin versus sorafenib tosylate alone overall survival patient hepatocellular carcinoma Child-Pugh Class A cirrhosis . Secondary - To evaluate effect regimen progression-free survival , time progression , time treatment failure , quality life ( QLQ-C30 FACT hep ) patient . - To evaluate benefit on-site monitoring versus centralize data management monitoring patient . - To characterize polymorphism specify haplotype diversity patient . - To test diagnostic prognostic signature quantitative RT-PCR determine predict response regimens . OUTLINE : This multicenter study . Patients stratify accord participate center , Cancer Liver Italian Program ( CLIP ) score ( 0 vs 1 vs 2-4 ) , WHO performance status ( 0 vs 1 v 2 ) , portal vein thrombosis ( presence v absence ) , extrahepatic metastasis ( presence v absence ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral sorafenib tosylate twice daily day 1-28 oral pravastatin daily day 1-28 . Courses repeat every 4 week absence disease progression unacceptable toxicity . - Arm II : Patients receive oral sorafenib tosylate twice daily day 1-28 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients complete quality-of-life questionnaire ( QLQ-C30 FACT ) baseline every 4 week completion study therapy . Blood tissue sample may collect laboratory analysis , include pharmacogenomic study . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hepatocellular carcinoma ( HCC ) , meet 1 follow criterion : Histologically confirm HCC If histological proof obtain ( e.g. , ascites , coagulation disorder ) , diagnosis may make case cirrhosis accord 2005 EASL/AASLD criterion demonstration focal hepatic lesion &gt; 10 mm , meet 1 follow criterion : Hypervascular tumor &lt; 2 cm 2 dynamicimaging technique ( e.g. , spiral CT scan , MRI scan , ultrasound contrast medium ) Hypervascular tumor ≥ 2 cm 1 dynamicimaging technique ( e.g. , spiral CT scan , MRI scan , ultrasound contrast medium ) No progressive disease follow prior treatment Not eligible curative treatment ( i.e. , transplantation , resection , percutaneous destruction ) chemoembolization Cancer Liver Italian Program ( CLIP ) prognosis score 0 4 ChildPugh score A No extrahepatic disease threaten short mediumterm vital prognosis PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy &gt; 12 week Transaminases ≤ 5 time upper limit normal ( ULN ) Serum creatinine ≤ 1.5 time ULN Not pregnant nursing Fertile patient must use effective contraception 3 month completion study therapy No cancerous pathology , except carcinoma situ cervix , superficial bladder tumor , treat basal cell carcinoma , cancer treat curatively ≥ 3 year ago No cardiac insufficiency ( NYHA class II IV congestive heart failure ) , arterial hypertension , uncontrolled arrhythmia , myocardial infarction within past 6 month No digestive hemorrhage within past month No major bleed disorder PRIOR CONCURRENT THERAPY : No prior concurrent statins No prior sorafenib tosylate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>